Diagnostics of lung cancer by fragmentated blood circulating cell-free DNA based on machine learning methods by Ivan O. Meshkov, Alexander P. Koturgin, Pavel V. Ershov, Liubov A. Safonova, Julia A. Remizova, Valentina V. Maksyutina, Ekaterina D. Maralova, Vasilisa A. Astafieva, Alexey A. Ivashechkin, Boris D. Ignatiev, Antonida V. Makhotenko, Ekaterina A. Snigir, Valentin V. Makarov, Vladimir S. Yudin, Anton A. Keskinov, Sergey M. Yudin, Anna S. Makarova, Veronika I. Skvortsova

“…Specificity values ranged from 79.3 to 90.0%.DiscussionThus, the CM has a good diagnostic value and does not require clinical or other data on tumor-associated biomarkers. The current method for LC detection has some advantages for future clinical implementation as a decision-making support system due to the performance of the CM requires data exclusively from NGS-analysis of blood plasma cfDNA fragmentation; the accuracy of the CM does not depend on any additional clinical data; the CM is highly interpretable and traceable; CM has appropriate modular architecture.…”
Get full text

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classifi... by Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang

“…These changes predominantly involved alterations in lipid metabolism, such as decreased diacylglycerol and sphingomyelin, which may impact tumor migration and invasion.…”
Get full text

ERBB4 selectively amplifies TGF-β pro-metastatic responses by Peihong Luo, Huanyu Hong, Baoling Zhang, Jie Li, Shuyi Zhang, Chaomin Yue, Jin Cao, Jia Wang, Yuhan Dai, Qingqing Liao, Pinglong Xu, Bing Yang, Xia Liu, Xia Lin, Yi Yu, Xin-Hua Feng

“…This discovery sheds light on the previously unrecognized role of SMAD4 as a substrate of ERBB4 and highlights the selective involvement of the ERBB4-SMAD4 regulatory axis in tumor metastasis.…”
Get full text

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer by Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff

“…The secondary outcomes were objective response rate, stratified by primary tumor sidedness, progression-free survival, and toxicity. …”
Get full text

Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017Research in context by Yi-Fan Wei, Li Ning, Yi-Lin Xu, Jing Ma, Dong-Run Li, Zan-Fei Feng, Fang-Hua Liu, Yi-Zi Li, He-Li Xu, Peng Li, Yong-Pei Yu, Dong-Hui Huang, Xiao-Ying Li, Song Gao, Chun-Qing Lin, Ting-Ting Gong, Qi-Jun Wu, Jing-He Lang

“…Although trends in subtypes also remained stable, ASRs increased over time for serous carcinomas and germ cell tumor in most countries, while mucinous carcinomas and adenocarcinoma NOS showed a decline. …”
Get full text

Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors by Changqun Liu, Yuening Cao, Yi Zuo, Chaozheng Zhang, Senmiao Ren, Xin Zhang, Chuanqi Wang, Yingjie Zeng, Jie Ling, Yilan Liu, Zixian Chen, Xiujun Cao, Zhengzhi Wu, Chuantao Zhang, Jun Lu

“…Importantly, compound 8 demonstrated potent in vivo anti-tumor activity in non-small cell lung cancer mouse models without visible toxicity. …”
Get full text

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study by Laura Moliner, MD, Núria Zellweger, MSc, Sabine Schmid, MD, Martina Bertschinger, MD, Christine Waibel, MD, Ferdinando Cerciello, MD, PhD, Patrizia Froesch, MD, Michael Mark, MD, Adrienne Bettini, MD, Pirmin Häuptle, MD, Veronika Blum, MD, Lisa Holer, MSc, Stefanie Hayoz, PhD, Martin Früh, MD, Samreen Ahmed, FRCP, MD, MBBS, MSc, Shradha Bhagani, MD, Nicola Steele, MD, Hannah-Leigh Gray, BSc, Stephen D. Robinson, MD, Michael Davidson, MD (Res), Samantha Cox, MD, MSc, MBBCh, Taha Khalid, MD, Tom R. Geldart, MD, Luke Nolan, FRCS, PhD, Deborah C. Scott, MBChB (MRCP), Lindsay Hennah, MD, Tom Newsom-Davis, MD, PhD, Emma Rathbone, MD, PhD, Catherine Handforth, MD, Arshi Denton, MD, Shairoz Merchant, PhD, Fiona Blackhall, MD, PhD, Laetitia A. Mauti, MD, Raffaele Califano, MD, Sacha I. Rothschild, MD, PhD

“…Patients received platinum-etoposide chemotherapy in combination with immunotherapy (atezolizumab or durvalumab). Patient, tumor, and treatment details were collected. Overall survival (OS), progression-free survival, objective response rate, and safety outcomes were analyzed. …”
Get full text

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network by Vincent Poindron, Benjamin Terrier, François Maillot, Jean-Pierre Gangneux, Nassim Kamar, Valéry Salle, Lilia Hasseine, François Danion, Lilia Merabet, Guillaume Desoubeaux, Éric Bailly, Milène Sasso, Antoine Néel, Simon Galmiche, Benjamin Thoreau, Stéphane Bretagne, Alexandre Alanio, André Paugam, Valérie Letscher-Bru, Sophie Cassaing, Hélène Guegan, Loïc Favennec, Alida Minoza, Florent Morio, Julie Bonhomme, Odile Eloy, Laurence Millon, Anne-Pauline Bellanger, Philippe Poirier, Maxime Moniot, Taieb Chouaki, Antoine Huguenin, Frédéric Dalle, Bernard Bouteille, Muriel Nicolas, Nicole Desbois-Nogard, Marie-Elisabeth Bougnoux, Karine Boukris-Sitbon, Fanny Lanternier, Caroline Mahinc, Marc Pihet, Magalie Demar, Céline Damiani, Marie-Fleur Durieux, Elena Charpentier, Cécile Nourrisson, Benoit Suzon

“…At IFD diagnosis, 365 (66.5%) patients received glucocorticoids (GCs), 285 (51.9%) immunosuppressants, 42 (7.7%) tumor necrosis factor (TNF)-α blockers, 75 (13.7%) other biologics. …”
Get full text

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA... by Carla Gaggiano, Antonio Vitale, Laura Obici, Giampaolo Merlini, Alessandra Soriano, Ombretta Viapiana, Marco Cattalini, Maria Cristina Maggio, Giuseppe Lopalco, Davide Montin, Masen Abdel Jaber, Lorenzo Dagna, Raffaele Manna, Antonella Insalaco, Matteo Piga, Francesco La Torre, Virginia Berlengiero, Viviana Gelardi, Luisa Ciarcia, Giacomo Emmi, Piero Ruscitti, Francesco Caso, Rolando Cimaz, José Hernández-Rodríguez, Paola Parronchi, Ludovico Luca Sicignano, Elena Verrecchia, Florenzo Iannone, Jurgen Sota, Salvatore Grosso, Carlo Salvarani, Bruno Frediani, Roberto Giacomelli, Maria Antonietta Mencarelli, Alessandra Renieri, Donato Rigante, Luca Cantarini

“…This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. …”
Get full text

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma by Inés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, Juan Carlos Soler-Perromat, Verónica González-Calle, David F. Moreno, Valentín Cabañas, Nieves López-Muñoz, Álvaro Bartolomé-Solanas, Marta Español-Rego, Juan Luis Reguera-Ortega, Laura Rosiñol, Lucía López-Corral, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Rosa Maria Alvarez Perez, Sara Varea, Eulàlia Olesti, Adolfo Gomez-Grande, Laura Frutos, Pilar Tamayo, Manel Juan, José M. Moraleda, Álvaro Urbano-Ispizua, E. Azucena González-Navarro, Joaquín Martínez-López, Maria-Victoria Mateos, Xavier Tomás, Xavier Setoain, Carlos Fernández de Larrea

“…Interestingly, [18F]FDG-PET/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of ≥25 cm3 at baseline [18F]FDG-PET/CT was associated with earlier disease progression and shorter OS. …”
Get full text

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab by Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

“…On multivariate Cox regression analysis, absence of portal vein tumor thrombus, ECOG <2, and continued active treatment were predictors of better PPS. mPPS was significantly longer for patients who continued active treatment vs. …”
Get full text

Effect of Lymphatic Drainage Manipulation on Knee Joint Swelling after Anterior Cruciate Ligament Reconstruction by MENG Cong, BAO Yong, ZHANG Weiming

“…Range of motion (ROM) and knee function [Lysholm knee score scale (LKSS)] before and after intervention for both groups were observed, as well as changes in pain substances [substance P, 5-hydroxytryptamine (5-HT)] and inflammatory markers [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)].ResultsThe swelling degree of knee joint in the observation group was lower than that in the control group at 1, 2 and 4 weeks postoperatively (<italic>P</italic>&lt;0.05). …”
Get full text

Progressive systemic inflammation precedes decompensation in compensated cirrhosis by Rubén Sánchez-Aldehuelo, Càndid Villanueva, Joan Genescà, Juan Carlos García-Pagán, Elisa Castillo, José Luis Calleja, Carles Aracil, Rafael Bañares, Luis Téllez, Lorena Paule, Rosa María Morillas, María Poca, Beatriz Peñas, Salvador Augustin, Juan G. Abraldes, Edilmar Alvarado-Tapias, Jaume Bosch, Agustín Albillos

“…We assessed markers of inflammation (interleukin-6 [IL-6], tumor necrosis factor-alpha, von Willebrand factor [vWF], C-reactive protein), macrophage activation (CD14, CD163), intestinal barrier integrity (fatty acid-binding protein [FABP], haptoglobin), and bacterial translocation (lipopolysaccharide [LPS]). …”
Get full text

Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis by Alessio Gerussi, Oliver Lester Saldanha, Giorgio Cazzaniga, Damiano Verda, Zunamys I. Carrero, Bastian Engel, Richard Taubert, Francesca Bolis, Laura Cristoferi, Federica Malinverno, Francesca Colapietro, Reha Akpinar, Luca Di Tommaso, Luigi Terracciano, Ana Lleo, Mauro Viganó, Cristina Rigamonti, Daniela Cabibi, Vincenza Calvaruso, Fabio Gibilisco, Nicoló Caldonazzi, Alessandro Valentino, Stefano Ceola, Valentina Canini, Eugenia Nofit, Marco Muselli, Julien Calderaro, Dina Tiniakos, Vincenzo L’Imperio, Fabio Pagni, Nicola Zucchini, Pietro Invernizzi, Marco Carbone, Jakob Nikolas Kather

Get full text

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y glo... by Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, Scott Gettinger, Heather Wakelee, Martin Sebastian, Mark Awad, Abdul Rafeh Naqash, Alessio Cortellini, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Marco Russano, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Alain Gelibter, Giuseppe Tonini, Amin H Nassar, Alessandra Curioni-Fontecedro, Eleni Karapanagiotou, Emilio Bria, Jack Bell, Paolo Bironzo, Joao V Alessi, Alessandro Morabito, David J Pinato, Francesco Passiglia, Carlo Genova, Francesca Mazzoni, Alessandro Inno, Francesco Grossi, Luca Cantini, Lorenza Landi, Luigi Della Gravara, Margarita Majem, Uma Mukherjee, Federica Biello, Alessandro Leonetti, Annalisa Guida, Marianna Macerelli, Gabriele Minuti, Giulio Metro, Thomas Newsom-Davis, Eleni Josephides, Andrea Camerini, Elisa Roca, David O’Reilly, Mingjia Li, Laura Mezquita, Teresa Gorría, Claudia A M Fulgenzi, Lauren Young, Joel W Neal, Javier Baena, Francesco Pantano, Jacobo Rogado, Mary Jo Fidler, Teresa Beninato, Federica Pecci, Alessandro Di Federico, Kazuki Takada, Leonardo Brunetti, Talal El Zarif, Laura Moliner, Alberto Servetto, Sukumar Kalvapudi, Sai Yendamuri, Edoardo Garbo, Giuseppina Rita Di Fazio, Monica Loza, Ritujith Jayakrishnan, Michele Montrone, Nichola O Awosika, Bartlomiej Tomasik, Maximilian Rost, Isabelle Monnet, Francesco Agustoni, Artur Katz, Dwight Hall Owen, Michele Ghidini, Armida D’Incecco, Gianpaolo Spinelli, Monica Verrico, Manuel Dupont, Rafael Di Marco Barros, Diego Luigi Cortinovis, Chiara Bennati, Frank Aboubakar Nana, Anne-Marie Dingemans, Taher Abu Hejleh

“…Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse.Methods This study assessed 5-year outcomes of first-line pembrolizumab monotherapy in a large, multicenter, real-world cohort of patients with advanced NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. …”
Get full text

TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study by Hao Xing, Delin Liu, Junlin Li, Yulu Ge, Xiaopeng Guo, Wenlin Chen, Dachun Zhao, Yixin Shi, Yilin Li, Yaning Wang, Yuekun Wang, Yu Xia, Jiaming Wu, Tingyu Liang, Hai Wang, Qianshu Liu, Shanmu Jin, Tian Qu, Siying Guo, Huanzhang Li, Tianrui Yang, Kun Zhang, Yu Wang, Wenbin Ma

“…ABSTRACT Background The 2021 WHO Classification of Central Nervous System Tumors introduces more molecular markers for glioma reclassification, including TERT promoter (TERTp) mutation as a key feature in glioblastoma diagnosis. …”
Get full text

Octreotide in the treatment of neuroendocrine carcinomas: Is the success achieved? by L. Yu. Morgunov

“…Diagnosis and treatment of functioning and non-functioning neuroendocrine tumors is a challenging task. Surgeru remains the only radical method of treatment of these tumors, but tumors often are diagnosed at the stage of metastasis, when only palliative treatment is possible. …”
Get full text

Giant ovarian serous cystadenoma. A case report by Jorge Luis Estepa Pérez, Tahiluma Santana Pedrasa, Daniel Olivera Fajardo

“…Ovarian tumors are not as common as uterus and breast tumors. …”
Get full text

Comparative immunohistochemical evaluation between primary and metastatic lesion in a feline osteosarcoma - A case report by Lyvia Cabral Ribeiro Carvalho, Camila Barbosa Amaral, Bárbara Paula dos Santos Batista, Ana Maria Reis Ferreira, Juliana da Silva Leite

“…Feline primary bone tumors are rare. Still, osteosarcoma (OSA) composes almost 80 % of malignant bone tumors in cats, affecting mostly elder feline individuals. …”
Get full text

Dysbiosis and extraintestinal cancers by Ruishan He, Pingqian Qi, Linzhen Shu, Yidan Ding, Peng Zeng, Guosheng Wen, Ying Xiong, Huan Deng

“…Additionally, we delve into the limitations inherent in current methodologies, particularly the challenges associated with differentiating low loads gut-derived microbiome within tumors from potential sample contamination or symbiotic microorganisms. …”
Get full text